Molecular Susceptibility and Treatment Challenges in Melanoma
Kiran Kumar Kolathur,
Radhakanta Nag,
Prathvi V Shenoy,
Yagya Malik,
Sai Manasa Varanasi,
Ramcharan Singh Angom,
Debabrata Mukhopadhyay
Affiliations
Kiran Kumar Kolathur
Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences (MCOPS), Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India
Radhakanta Nag
Department of Microbiology, College of Basic Science & Humanities, Odisha University of Agriculture & Technology (OUAT), Bhubaneswar 751003, Odisha, India
Prathvi V Shenoy
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences (MCOPS), Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India
Yagya Malik
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences (MCOPS), Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India
Sai Manasa Varanasi
Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA
Ramcharan Singh Angom
Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA
Debabrata Mukhopadhyay
Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA
Melanoma is the most aggressive subtype of cancer, with a higher propensity to spread compared to most solid tumors. The application of OMICS approaches has revolutionized the field of melanoma research by providing comprehensive insights into the molecular alterations and biological processes underlying melanoma development and progression. This review aims to offer an overview of melanoma biology, covering its transition from primary to malignant melanoma, as well as the key genes and pathways involved in the initiation and progression of this disease. Utilizing online databases, we extensively explored the general expression profile of genes, identified the most frequently altered genes and gene mutations, and examined genetic alterations responsible for drug resistance. Additionally, we studied the mechanisms responsible for immune checkpoint inhibitor resistance in melanoma.